Ibex Technologies (TSE:IBT) has released an update.
Ibex Technologies Inc., a player in the biotech sector, reported a revenue increase of 12% for Q2 and 15% over six months, primarily due to strong performance in the hemostasis market. Despite the revenue growth, the company experienced a decline in net earnings, attributed to costs related to its impending acquisition by BBI Solutions OEM Limited. The company also announced a special shareholder meeting to vote on the acquisition, with the board recommending approval of the sale at $1.45 per share.
For further insights into TSE:IBT stock, check out TipRanks’ Stock Analysis page.
